154 related articles for article (PubMed ID: 1385056)
21. Pancreatic cystic neoplasm: the role of cyst morphology, cyst fluid analysis, and expectant management.
Leung KK; Ross WA; Evans D; Fleming J; Lin E; Tamm EP; Lee JH
Ann Surg Oncol; 2009 Oct; 16(10):2818-24. PubMed ID: 19536601
[TBL] [Abstract][Full Text] [Related]
22. Mucinous biliary cystadenoma with mesenchymal stroma: expressions of CA 19-9 and carcinoembryonic antigen in serum and cystic fluid.
Lee JH; Chen DR; Pang SC; Lai YS
J Gastroenterol; 1996 Oct; 31(5):732-6. PubMed ID: 8887044
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical detection of CEA, CA19-9, and DF3 in esophageal carcinoma limited to the submucosal layer.
Ikeda Y; Kuwano H; Ikebe M; Baba K; Toh Y; Adachi Y; Sugimachi K
J Surg Oncol; 1994 May; 56(1):7-12. PubMed ID: 8176946
[TBL] [Abstract][Full Text] [Related]
24. [An autopsy case of a gastric cancer associated with elevated AFP, CEA and CA19-9].
Nakamura Y; Hozumi T; Ohkita M; Masuda S; Maeda M; Okada K; Chinzei T; Yamashiro K; Harui M; Hosokawa I
Gan No Rinsho; 1988 Feb; 34(2):213-8. PubMed ID: 2450214
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma.
Qiu Y; He J; Chen X; Huang P; Hu K; Yan H
Clin Chim Acta; 2018 May; 480():186-192. PubMed ID: 29438681
[TBL] [Abstract][Full Text] [Related]
27. [Significances of serum level and immunohistochemical stain of CA19-9 in simple hepatic cysts and intrahepatic biliary cystic neoplasms].
Park KH; Kim JS; Lee JH; Kim HJ; Kim JY; Yeon JE; Park JJ; Byun KS; Bak YT; Lee CH
Korean J Gastroenterol; 2006 Jan; 47(1):52-8. PubMed ID: 16434869
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
29. Tumor markers panel and tumor size of ovarian dermoid tumors in reproductive age.
Var T; Tonguc EA; Ugur M; Altinbas S; Tokmak A
Bratisl Lek Listy; 2012; 113(2):95-8. PubMed ID: 22394039
[TBL] [Abstract][Full Text] [Related]
30. Tumour associated antigens in diagnosis of serous effusions.
Mezger J; Permanetter W; Gerbes AL; Wilmanns W; Lamerz R
J Clin Pathol; 1988 Jun; 41(6):633-43. PubMed ID: 2454957
[TBL] [Abstract][Full Text] [Related]
31. CA9 as a molecular marker for differential diagnosis of cystic renal tumors.
Li G; Bilal I; Gentil-Perret A; Feng G; Zhao A; Peoc'h M; Genin C; Tostain J; Gigante M
Urol Oncol; 2012; 30(4):463-8. PubMed ID: 20822935
[TBL] [Abstract][Full Text] [Related]
32. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
33. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance.
Gebauer G; Müller-Ruchholtz W
Anticancer Res; 1997; 17(4A):2731-4. PubMed ID: 9252706
[TBL] [Abstract][Full Text] [Related]
34. Cyst fluid analysis in the differential diagnosis of pancreatic cysts. A comparison of pseudocysts, serous cystadenomas, mucinous cystic neoplasms, and mucinous cystadenocarcinoma.
Lewandrowski KB; Southern JF; Pins MR; Compton CC; Warshaw AL
Ann Surg; 1993 Jan; 217(1):41-7. PubMed ID: 8424699
[TBL] [Abstract][Full Text] [Related]
35. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
Kuusela P; Haglund C; Roberts PJ; Jalanko H
Br J Cancer; 1987 Jun; 55(6):673-6. PubMed ID: 2441731
[TBL] [Abstract][Full Text] [Related]
36. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.
Jalanko H; Kuusela P; Roberts P; Sipponen P; Haglund CA; Mäkelä O
J Clin Pathol; 1984 Feb; 37(2):218-22. PubMed ID: 6198342
[TBL] [Abstract][Full Text] [Related]
37. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA.
Maestranzi S; Przemioslo R; Mitchell H; Sherwood RA
Ann Clin Biochem; 1998 Jan; 35 ( Pt 1)():99-103. PubMed ID: 9463746
[TBL] [Abstract][Full Text] [Related]
38. CEA and CA 19-9 in benign pulmonary or mediastinal cystic lesions.
Uyama T; Monden Y; Sumitomo M; Miura K; Kimura S
J Surg Oncol; 1989 Jun; 41(2):103-8. PubMed ID: 2724976
[TBL] [Abstract][Full Text] [Related]
39. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
Kataoka A; Yakushiji M
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
[TBL] [Abstract][Full Text] [Related]
40. Intracystic concentrations of tumour markers for the diagnosis of cystic liver lesions.
Fuks D; Voitot H; Paradis V; Belghiti J; Vilgrain V; Farges O
Br J Surg; 2014 Mar; 101(4):408-16. PubMed ID: 24477793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
